Nilotinib capsules bulk supplier for pharma manufacturers

Nilotinib Capsules 150 mg and 200 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 150 mg and 200 mg

Reference Brands: Tasigna(US & EU)

Nilotinib is a tyrosine kinase inhibitor that blocks BCR-ABL fusion protein activity in chronic myeloid leukemia (CML). It reduces abnormal cell proliferation, induces apoptosis, and improves long-term survival. Benefits include effective disease control, decreased progression risk, and improved quality of life for CML patients.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Nilotinib capsules, marketed as Tasigna, are approved in the US by the FDA and in the EU via EMA for treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML). Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing quality, and pharmacovigilance plans. The FDA reviews clinical trial and manufacturing data for timely approval, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper adherence to regional requirements supports swift approval, safe use, and worldwide availability, enabling effective long-term disease management for CML patients across regions.

Nilotinib Capsules — third party manufacturing & bulk supply

Nilotinib Capsules 150 mg and 200 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Nilotinib Capsules is supplied as Capsules — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Nilotinib Capsules listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Nilotinib Capsules →

Back to Listing

Frequently Asked Questions

Nilotinib is used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults and pediatric patients. It is prescribed for newly diagnosed patients as well as for those who are resistant or intolerant to prior therapies such as imatinib. It works by blocking abnormal BCR-ABL tyrosine kinase activity that drives leukemia cell growth.

Nilotinib is made from the active pharmaceutical ingredient nilotinib hydrochloride monohydrate, which is a targeted tyrosine kinase inhibitor designed to specifically inhibit BCR-ABL signaling in leukemia cells.

The main trade name of nilotinib is Tasigna.

The original brand Tasigna is developed and marketed by Novartis. Generic versions may also be manufactured by other approved pharmaceutical companies in some markets.

The generic name is nilotinib hydrochloride monohydrate.

The brand name is Tasigna.

Nilotinib is manufactured in regulated pharmaceutical facilities across the USA, EU, UK, and other countries depending on the manufacturer and marketing authorization holder.